I will try to attend this year wonder how they would like it if I bring an 18 month old to ask the question what will be left of my college fund if executives keep taking big bonuses before they monetize anything for the shareholders.
taz: that's a very interesting and most unusual comment by an accountant! Maybe a lawyer would say something like that, but an accountant???
Are you planning to go to this year's meeting?
If so, could you please ask the following questions if they haven't been brought up? I've noticed that they only appear to take phone questions from "analysts."
Does GERN have all the information needed for a complete response to the FDA Hold? No waffling from chippy! Yes or No.
If yes, when do they anticipate issuing a response?
If no, when do they anticipate getting the necessary data?
Here is one for you the nuclear transfer technology owned by Geron from the dolly cloning IP has now been used to make theraputic cloned Stem Cell lines and the process first published last year has now been repeated so it is confirmed. When I asked the BOD last year about this issue and if Geron still owned the IP I was told they did still own it. When I asked if they would protect it or liscense it out I was challenged by the Accountant and told they never would based on religious and ethical reasons. The last time I looked Corperations have no religion.
granger: Dr. T is a proven "winner." No doubt about that!
GERN management is a proven "loser." No doubt about that either! (end: not being negative, just being realistic and telling how it has been over the past 15 years)
Does one cancel out the other?
Time will tell.
Of course, IMO.
I think you can call this, "The Tefferi Fear Factor". For some reason some have no faith in Dr. T, and believe that he is a self-promoter without any credibility. Mayo would not allow that. I would say that nothing is impossible, but the odds are at least 99% against that. Geron and the success of Imetelstat look like a very good bet ("betting the house" may be a bit risky from a prudent investment point of view).
High school, it is not huge at all, though it depends on the mind behind the eyes that examine what is before them. It altered the application of the drug for ARIAD and that was what mattered in the end, though no pharma is allowed to mislead patients or doctors through their marketing with false or misleading information. The steps involved in clnical trials are not more important than numbers and results. Moreover, if you go to clinicaltrials gov and search for Iclusig or ponatinib and imetelstat separately, then you'll see that Geron likely has more qualitative data and completed studies, whereas ARIAD has a similar list, but with a large number with recruitment and incomplete studies. Overall in an average phase III clinical trial one might expect over a 1000 patients and maybe 2000-3000 or so patients, but ARIAD's total patient number is around 450 patients. If we throw in Tefferi's patients, then I am thinking that Geron is not far behind with overall numbers of exposed patients over the years and maybe ahead with qualitative data. The FDA wants data on the reversibility of the liver function disorders, though they did not require this initially, and Geron scientists brushed this low-grade liver problem aside; there could still be data on rebounding liver function from follow-up tests. Does Geron have some qualitative and quantitative data on the liver function tests, or any biopsy data?
It will be a big surprise, if it comes that soon. Though many of us here wish it would be done by that time, it will likely take months longer. I plan to write a letter to the FDA, and others should do so, too. I don't see why the FDA could not shift its policy to allow for slow progress with altered monitoring of liver functions. Also, I cannot avoid the possibility that along with myelosuppression comes immunosuppression, and with these endotoxins forming from microbial proliferation in the gastrointestinal system. Endotoxins would affect liver function in a similar way to that of the toxic levels of ethanol. I should ask whether researchers have examined this regarding the liver function, and whether antibiotic treatments might help reduce the liver function disorders?
In other words take Dr. Tefferi and the MAYO out of the equation and what are you left with?
Maybe we should just scrap Scarlet altogether and pay Tefferi the $million. It wouldn't be hard to vote Chippy off the gerny considering he hardly owns any shares.
Ignorance is the rule today and not the exception, and ignorance rules. Don't bother with research of established facts and truths because these just get in the way of a good opinion. Opinions are far more important than facts. It's a major part of the blight of modernity. If you go to clinicaltrials gov and search for curcumin, then you'll see that the study is complete on multiple myeloma and there are multiple trials underway. However, if there were remissions in multiple myeloma, as the listed study, which ran from roughly 2005 to 2011, we would know about them in the science literature, and the trials would have been expanded. Let us hope that it will be efficacious for some of the listed diseases. Nonetheless, it seems to me that you imply that there are no natural toxins, and again ignorance rules. Arsenic is common in ground water, and it's natural, along with millions of other natural toxins. Warfarin, which is on market for decades as an anticoagulant was derived, and still occurs in wild and cultivated plants. Don't forget drinking alcohol, ethanol, which is natural and gives us the most common occurrence of intoxication. Toxic levels bring on intoxication, or poisoning. You need to stumble into a hornets' nest or some poison ivy for a basic lesson in natural toxins, or try manchineel, or the husk of cashews, ergots, aflatoxin or other mycotoxins, or foxglove. I could go with this, but you should now get the point?